(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/210193 A1

(51) International Patent Classification:

C07D 401/04 (2006.01)	*A61P 11/00* (2006.01)
C07D 401/14 (2006.01)	*A61P 17/00* (2006.01)
C07D 405/12 (2006.01)	*A61P 27/00* (2006.01)
C07D 405/14 (2006.01)	*A61P 29/00* (2006.01)
C07D 471/04 (2006.01)	*A61P 31/00* (2006.01)
C07D 493/08 (2006.01)	*A61P 35/00* (2006.01)
A61K 31/4709 (2006.01)	*C07D 413/14* (2006.01)
A61P 3/00 (2006.01)	*C07D 417/14* (2006.01)

(21) International Application Number:
PCT/EP2025/059194

(22) International Filing Date:
03 April 2025 (03.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24168329.1 03 April 2024 (03.04.2024) EP

(71) Applicants: **NXI THERAPEUTICS AG** [CH/CH]; Spitalstrasse 41, 4056 Basel (CH). **UNIVERSITÄT BASEL** [CH/CH]; Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH).

(72) Inventors: **JAYACHANDRAN, Rajesh**; c/o NXI Therapeutics AG, Spitalstrasse 41, 4056 Basel (CH). **PIETERS, Jean**; c/o Universität Basel, Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH). **ERNI, Reto**; c/o NXI Therapeutics AG, Spitalstrasse 41, 4056 Basel (CH). **HERRENDORFF, Ruben**; c/o NXI Therapeutics AG, Spitalstrasse 41, 4056 Basel (CH). **GEORGE, Pascal**; 11 Route de Rochefort, 78730 Longvilliers (FR). **JIMENEZ TEJA, Daniel**; c/o EVOTEC, 195 Route d'Espagne, 31000 Toulouse (FR). **GRATIEN, Gilles-Olivier**; c/o EVOTEC, 195 Route d'Espagne, 31000 Toulouse (FR).


(74) Agent: **VOSSIUS & PARTNER PATENTANWÄLTE RECHTSANWÄLTE MBB**; Siebertstraße 3, 81675 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: 4-(HETERO)ARYL-7-(HETERO)ARYL-2-METHYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES AS CORONIN-1 MODULATORS



(I)

(57) Abstract: The present invention relates to immunosuppressive compounds that deplete coronin 1 levels, in particular to coronin 1 promoter inhibitors. Accordingly, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, or solvate thereof. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a pharmaceutical composition comprising the compound of the present invention and a pharmaceutically acceptable carrier.

WO 2025/210193 A1